(19)

(11)

EP 4 816 381 A1

(12)

(43) Date of publication: 07.10.2026 Bulletin 2026/41 (21) Application number: 24895272.3 (22) Date of filing: 29.11.2024

(51) International Patent Classification (IPC):  C07K 7/06(2006.01) A61P 35/00(2006.01) A61K 51/08(2006.01) C07K 1/13(2006.01) (52) Cooperative Patent Classification (CPC): C07K 7/06; A61P 35/00; A61K 51/088 (86) International application number: PCT/CA2024/051594 (87) International publication number: WO 2025/111712 (05.06.2025 Gazette 2025/23)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 29.11.2023 US 202363603961 P (71) Applicants: Alpha-9 Oncology Inc. Vancouver, BC V5T 1M4 (CA) Provincial Health Services Authority Vancouver, BC V5Z 1L3 (CA) The University of British Columbia Vancouver, British Columbia V6T 1Z3 (CA)

(72) Inventors: ZHANG, Chengcheng Vancouver, British Columbia V5T 1M4 (CA) WANNER, Jutta Vancouver, British Columbia V5T 1M4 (CA) LIN, Kuo-shyan Vancouver, British Columbia V5Z 1L3 (CA) WANG, Lei Vancouver, British Columbia V6T 1Z3 (CA) (74) Representative: Cooley (UK) LLP  22 Bishopsgate London EC2N 4BQ London EC2N 4BQ (GB)